PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

MammoRisk — used in conjunction with mammograms — is designed to determine breast cancer risk using a patient's age, breast density, family history, and breast biopsy history, as well as a polygenic score based on the analysis of disease-linked genetic variations from a saliva sample.

Under the terms of their deal, the Institut Curie will perform MammoRisk genetic analyses, focusing on roughly 100 polymorphisms associated with increased breast cancer risk. The partners also intend to work together on future breast cancer-related research projects, Villejuif, France-based PrediLife said.

Additional terms were not disclosed.

"The collaboration underscores the ability of the Institut Curie's genomics platform to provide academic and industrial partners such as PrediLife with technological tools for high-throughput genomic analysis," David Gentien, head of the institute's genomics platform, said in a statement.